Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) received approval from the US Food and Drug Administration to conduct phase one clinical trials for HLX99.
The drug is used for the treatment of amyotrophic lateral sclerosis, according to a Monday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% in recent trade.